Clinical Trial Update: Anti-Xa Levels in Critically Ill Patients Receiving Low-molecular-weight Heparin for Thromboprophylaxis in China

View source ↗

Summary

This ClinicalTrials.gov entry reports an update on anti-Xa level monitoring in critically ill patients receiving low-molecular-weight heparin for thromboprophyl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Critical Illness

Drugs mentioned

• Dalteparin (dalteparin)
• Enoxaparin (enoxaparin sodium)

Snippet

Sponsor: Southeast University, China | Conditions: Critically Ill, Anti-Xa | Status: UNKNOWN